Proteinuria – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Proteinuria – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Camostat Mesilate for Kidney Protection in Patients with Chronic Kidney Disease and Proteinuria https://clinicaltrials.eu/trial/study-on-the-effects-of-camostat-mesilate-for-kidney-protection-in-patients-with-chronic-kidney-disease-and-proteinuria/ Wed, 29 Apr 2026 15:05:32 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-camostat-mesilate-for-kidney-protection-in-patients-with-chronic-kidney-disease-and-proteinuria/ This clinical trial is focused on studying the effects of a medication called Camostat Mesilate on individuals with Chronic Kidney Disease (CKD) who also have proteinuria, which means there is an excess of protein in their urine. The purpose of the study is to evaluate how Camostat Mesilate affects the body’s ability to excrete salt and water, as well as its impact on total body water content and blood pressure in patients with CKD compared to healthy individuals.

Participants in the study will take Camostat Mesilate in the form of a tablet. The study will monitor various health indicators, including urine sodium and water excretion, body weight, and blood pressure at home. Additionally, the study will look at urine protease activity, which involves enzymes that break down proteins, and other markers in the urine and blood that can provide insights into kidney function and health.

The study will take place over a period of time, with participants being closely monitored to understand the effects of the medication. The goal is to gather information that could help improve treatment options for people with CKD. Participants will be required to maintain their usual antihypertensive treatment, which is medication to manage high blood pressure, throughout the study. The study is expected to conclude by the end of 2025.

]]> Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB https://clinicaltrials.eu/trial/study-on-finerenone-for-children-with-chronic-kidney-disease-and-proteinuria-using-acei-or-arb/ Wed, 29 Apr 2026 14:47:41 +0000 https://clinicaltrials.eu/trial/study-on-finerenone-for-children-with-chronic-kidney-disease-and-proteinuria-using-acei-or-arb-2/ This clinical trial is focused on studying the effects of a medication called finerenone in children with chronic kidney disease and proteinuria. Chronic kidney disease is a condition where the kidneys are damaged and cannot filter blood as well as they should, while proteinuria is the presence of excess protein in the urine, which can be a sign of kidney damage. The study will involve children aged 6 months to under 18 years who are already being treated with medications known as angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), which help manage blood pressure and reduce kidney damage.

The purpose of the study is to evaluate how well finerenone works in reducing the amount of protein in the urine when used alongside ACEI or ARB. Participants will be randomly assigned to receive either finerenone or a placebo, which is a substance with no active medication. The study will last for six months, during which the children will take the medication in the form of film-coated tablets or granules for oral suspension, depending on their age and body weight. The study will monitor how the medication moves through the body and its effects on the body, including any side effects.

Throughout the study, researchers will collect information on changes in the urinary protein-to-creatinine ratio, which is a measure of protein levels in the urine. They will also track any side effects, changes in blood pressure, and kidney function. The study aims to determine if finerenone is more effective than a placebo in reducing protein levels in the urine, which could help improve kidney health in children with chronic kidney disease and proteinuria.

]]> Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-finerenone-with-ace-inhibitors-or-arbs-for-children-and-young-adults-with-chronic-kidney-disease-and-proteinuria/ Wed, 29 Apr 2026 14:30:40 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-finerenone-with-ace-inhibitors-or-arbs-for-children-and-young-adults-with-chronic-kidney-disease-and-proteinuria/ This clinical trial is focused on studying the safety of a medication called finerenone in children and young adults aged 1 to 18 years who have chronic kidney disease and a condition called proteinuria, which means there is an excess of protein in the urine. The study will explore how safe it is to use finerenone over a long period when taken alongside another type of medication, either an ACE inhibitor or an angiotensin receptor blocker (ARB). These medications are commonly used to help manage blood pressure and protect the kidneys.

Participants in the study will take finerenone in the form of either a film-coated tablet or granules for oral suspension, depending on their age and body weight. The study will last for 18 months, during which time the participants will continue their usual treatment with an ACE inhibitor or ARB. The goal is to ensure that adding finerenone to their treatment is safe over this extended period.

Throughout the study, researchers will monitor the participants for any side effects and changes in their health, such as variations in blood pressure and potassium levels. The study aims to provide valuable information on the long-term safety of finerenone for young patients with chronic kidney disease and proteinuria, helping to improve treatment options for this condition.

]]>